Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783302 · ClinicalTrials.gov registry record
Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care
A clinical trial, sponsored by GE Healthcare.
- Completed
- Registry status
- 885
- Enrollment target
NCT00783302: Completed study, sponsored by GE Healthcare.
NCT00783302 is a clinical trial that has completed, run by GE Healthcare. The registered enrollment target is 885 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00783302 has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- 885 participants
- Enrollment target
Study Summary
To assess prognostic value of CCTA examination in subjects who undergo CCTA as part of their medical care when compared to a standard of truth, i.e. subject outcomes during each follow-up period.
Primary Outcome
Statistical analysis of the Sensitivity of Visipaque-enhanced CCTA for predicting downstream cardiovascular events at each follow-up period when compared to the SoT. The results are calculated as percentage of participants.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 885 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-04 |
What the finished NCT00783302 record still lists
NCT00783302 is an observational study that tracks outcomes without assigning an intervention. The registered 885 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00783302 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00783302 about?
NCT00783302 is a clinical study titled "Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care". To assess prognostic value of CCTA examination in subjects who undergo CCTA as part of their medical care when compared to a standard of truth, i.e. subject outcomes during each follow-up period.
What is the current status of trial NCT00783302?
This trial is currently completed. The enrollment target is 885 participants. The study started on 2008-09. Estimated completion is 2011-04.
Who is sponsoring clinical trial NCT00783302?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia